International Sales Veteran to Lead Certara’s Emerging Translational Pharmacology Business Group in Europe

ST. LOUIS, Mo.–Certara™, a global, emerging translational pharmacology company, formed by the acquisition of Pharsight® Corporation by Tripos™, today announced the appointment of William Cobert to lead its European sales group. Mr. Cobert will manage a combined sales team for Tripos and Pharsight, leading the effort to closely coordinate the delivery of products and services to numerous multi-national clients served by Tripos and Pharsight.

“William brings more than three decades of experience building strong European sales teams in life sciences and other technology-intensive industries,” said James Hayden, Senior Vice President for Global Sales for Certara. “That extensive experience, coupled with his leadership skills, makes him ideal for this important position. Certara’s key objective is to eliminate the roadblocks and hurdles that often exist between the phases of research, so that breakthrough discoveries will occur more rapidly. William understands how critical that is in helping customers across discovery and development.”

William Cobert has 33 years of direct experience in sales, sales management and administration in life sciences and biotech industries. Before joining the Certara team, William was Vice President Europe for Spotfire Inc., and was responsible for all European sales and pre-sales operations. He has also held key management positions with VA Linux Systems, and Silicon Graphics in Europe.

“Certara’s powerful combination of Tripos and Pharsight, in Europe and throughout the world, gives our customers a distinct advantage as the industry makes increasing use of translational pharmacology to improve throughput and decision-making,” said Mr. Cobert. “Integrating the flow of information throughout the research process saves time and resources, and improves productivity at every stage.”

About Certara

Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos (www.tripos.com) and Pharsight Corporation (www.pharsight.com). Tripos is a global leader in innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight is the leading provider of software and scientific services to improve productivity and decision-making in clinical drug development. Certara expects to provide its clients with important new products, key enabling technologies and scientific expertise to expedite the flow of information throughout drug discovery and development. Certara is focused on reducing the barriers between the phases of research that will speed discoveries in chemistry and enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.